2018
Cell-Based Immunotherapy of Gliomas
Everson R, Antonios J, Liau L. Cell-Based Immunotherapy of Gliomas. Progress In Neurological Surgery 2018, 32: 90-100. PMID: 29990977, DOI: 10.1159/000469683.Peer-Reviewed Original ResearchMeSH KeywordsBrain NeoplasmsCancer VaccinesCell- and Tissue-Based TherapyDendritic CellsGliomaHumansImmunotherapy, ActiveImmunotherapy, AdoptiveConceptsCellular immunotherapyImmune cellsDendritic cell (DC)-based vaccinesTreatment of malignant gliomasCellular immunotherapy approachesAntitumor immune cellsAntitumor responseAdoptive transferImmunotherapy approachesActive immunotherapyLive immune cellsMalignant gliomasEffector capabilitiesPassive immunotherapyImmunotherapyImmune responseEx vivoImmune systemGlioma cellsCell typesPatientsGliomaCellsNeoplasms
2016
TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination
Hsu M, Sedighim S, Wang T, Antonios J, Everson R, Tucker A, Du L, Emerson R, Yusko E, Sanders C, Robins H, Yong W, Davidson T, Li G, Liau L, Prins R. TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunology Research 2016, 4: 412-418. PMID: 26968205, PMCID: PMC4873445, DOI: 10.1158/2326-6066.cir-15-0240.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesT cell receptorT-cell receptor sequencingImmune responseOverall survivalPeripheral bloodIncreased time to progressionTumour-infiltrating lymphocytes contentAssessment of tumor-infiltrating lymphocytesPredictors of immune responseAntigen-specific immune responsesTime to progressionDendritic cell immunotherapyDC vaccinesCell immunotherapyImmunotherapeutic strategiesSurvival outcomesStatistically significant correlationT cellsClinical outcomesAdjunctive treatmentBrain tumorsImmunotherapyNext-generation sequencing approachTumor
2015
Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma
Everson R, Antonios J, Lisiero D, Soto H, Scharnweber R, Garrett M, Yong W, Li N, Li G, Kruse C, Liau L, Prins R. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro-Oncology 2015, 18: 368-378. PMID: 26330563, PMCID: PMC4767237, DOI: 10.1093/neuonc/nov153.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, NeoplasmAzacitidineCell Line, TumorDecitabineDisease Models, AnimalGlioblastomaHumansImmunotherapy, AdoptiveMiceT-LymphocytesConceptsNY-ESO-1NY-ESO-1-specific T cellsCells treated with decitabineDiffusely infiltrating tumor cellsAdoptive T cell therapyIntracranial human glioma xenograftsT-cell therapyDemethylating agent decitabineTumor rejection antigensGlioma-bearing miceSignificant survival benefitSquamous cell carcinomaPhenotype of lymphocytesT cell traffickingInfiltrating tumor cellsIdeal treatment modalityReal-time cytotoxicity assayHuman glioma xenograftsHuman glioblastoma cell culturesLong-term survivalClinically feasible strategyLong-term survival of animalsIn vitro treatmentTreatment of glioblastomaGlioblastoma cell cultures